Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the effectiveness of 3D-printed liver models in hepatobiliary surgery planning compared to traditional digital simulations. It is conducted in three phases:
The study was conducted in three phases to assess the effectiveness of 3D-printed liver models for hepatobiliary surgery planning, comparing these models with traditional digital simulations.
Phase One: This phase involved the development and validation of 35 3D-printed liver models. The focus was on timeliness, cost, precision, and alignment with digital planning tools. The goal was to ensure that the physical models accurately represented the liver's anatomy as planned digitally.
Phase Two: In this phase, the 3D reconstruction process was optimized using deep learning techniques. The study compared AI-assisted automatic segmentation with manual methods to enhance the accuracy and efficiency of the models. This phase aimed to streamline the model creation process and reduce the time and effort required.
Phase Three: This phase conducted a retrospective comparative analysis involving 64 patients who underwent hepatobiliary surgery. These patients were divided into two groups: one group used validated physical 3D models, and the other group used digital simulations for surgical planning. The phase evaluated various surgical outcomes, including the extent of resection, operation time, intraoperative blood loss, and hospitalization duration. The primary objective was to determine the clinical effectiveness of using 3D-printed models compared to traditional digital simulations in hepatobiliary surgery planning.
By systematically analyzing these three phases, the study aims to provide comprehensive insights into the benefits and potential limitations of using 3D-printed models in surgical planning, ultimately enhancing patient outcomes and surgical precision.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 3D Printed Model Group (3DP) | Experimental | Participants in this group will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. The surgical procedures will be guided by these 3D-printed models. |
|
| 3D Virtual Model Group (3DV) | Experimental | Participants in this group will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. The surgical procedures will be guided by these digital simulations. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3D-Printed Liver Model | Device | Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures. |
| Measure | Description | Time Frame |
|---|---|---|
| Intraoperative Blood Loss | Measure the volume of blood loss during surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome assesses the efficacy of using 3D-printed liver models in reducing intraoperative blood loss compared to digital simulations. | During the surgery |
| Blood Transfusion | Assess the need for intraoperative blood transfusions for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of using 3D-printed liver models on the necessity for transfusions. | During the surgery |
| Operation Duration | Measure the total duration of the surgical procedure for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome assesses whether the use of 3D-printed models can reduce operation time. | During the surgery |
| Surgical Margin Status | Assess the status of surgical margins post-resection to determine the precision of tumor removal in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). R0 indicates no residual tumor, R1 indicates microscopic residual tumor. | Immediately after surgery |
| Postoperative Hospital Stay | Measure the length of hospital stay post-surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of 3D-printed models on postoperative recovery time. | From surgery to discharge |
| Postoperative Complications |
| Measure | Description | Time Frame |
|---|---|---|
| Age | Document the age of each patient at the time of surgery in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). | Before surgery |
| Sex | Record the sex of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Hebei University | Baoding | Hebei | 071000 | China |
The plan includes sharing deidentified individual participant data (IPD) including study protocol, statistical analysis plan (SAP), informed consent form (ICF), clinical study report (CSR), and analytic code.
The data will be available starting 6 months after the publication and will be accessible for 5 years.
Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to [lilinqian163@163.com]. To gain access, data requestors will need to sign a data access agreement.
Not provided
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
This study involves three phases. Phase one focuses on developing and validating 3D-printed liver models. Phase two optimizes the 3D reconstruction process using AI-assisted segmentation. Phase three is a randomized controlled trial comparing surgical outcomes using physical 3D models versus digital simulations.
Not provided
Not provided
he random allocation sequence was implemented using sequentially numbered, opaque sealed envelopes, each containing a card indicating group assignment. An independent administrative staff member, not involved in enrollment or treatment, prepared the envelopes. To conceal the allocation sequence, envelopes were stored in a secure, locked cabinet accessible only to the study coordinator, who was not involved in patient evaluations or surgeries. This maintained clinician blindness to allocations, preserving the integrity of the randomization process. Third-party medical staff, blinded to group allocation, evaluated the outcomes to ensure objective assessment.
| Digital Simulation-Based Surgical Planning | Procedure | Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures. |
|
Measure the length of hospital stay post-surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of 3D-printed models on postoperative recovery time.
| From the date of surgery until discharge, assessed up to 30 days. |
| Before surgery |
| BMI (Body Mass Index) | Measure and record the Body Mass Index (BMI) of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). | Before surgery |
| AFP (Alpha-Fetoprotein) | Measure the levels of Alpha-Fetoprotein (AFP) in the blood of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV) to assess liver cancer biomarkers. | Before surgery |
| Tumor Size | Measure the size of the tumor in each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). | During the surgery |
| Presence of Liver Cirrhosis | Record whether each patient has liver cirrhosis in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). | Before surgery |
| HBV DNA Levels | Measure the levels of HBV DNA in the blood of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV) to assess the presence and extent of hepatitis B infection. | Before surgery |